Navigation Links
Quest Diagnostics to Speak at the William Blair & Company 29th Annual Growth Stock Conference
Date:6/8/2009

MADISON, N.J., June 8 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the William Blair & Company 29th Annual Growth Stock Conference in Chicago on Tuesday, June 9, 2009. The Quest Diagnostics presentation is scheduled to begin at 8:10 a.m. Central Time.

During the conference, the company will reaffirm its 2009 guidance for revenue growth of approximately 3%, operating income to approximate 18% of revenues, and earnings per diluted share from continuing operations of between $3.65 and $3.75.

The presentation will be webcast live during the conference and will be available to registered investors on the following site: http://www.wsw.com/webcast/blair17/dgx and to the public on www.QuestDiagnostics.com/investor. In addition, the archived webcast will be available immediately following the conclusion of the live event and will remain available until July 9, 2009.

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at www.QuestDiagnostics.com.

The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers and strategic partners and other factors discussed in "Business" in Part I, Item 1, "Risk Factors" and "Cautionary Factors that May Affect Future Results" in Part I, Item 1A, "Legal Proceedings" in Part I, Item 3, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Part II, Item 7 and "Quantitative and Qualitative Disclosures About Market Risk" in Part II, Item 7A in the company's 2008 Annual Report on Form 10-K and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk" in the company's 2009 Quarterly Report on Form 10-Q and other items throughout the Form 10-K and the company's 2009 Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.


'/>"/>
SOURCE Quest Diagnostics Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Effectiveness of mouse breeds that mimic Alzheimers disease symptoms questioned
2. The 7 Key Questions About the Schwarzenegger/Nunez Health Care Compromise
3. LifeQuest Announces End of Immunity Health Challenge Contest
4. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
5. Quest Diagnostics to Speak at the Bear Stearns Healthcare Conference
6. Study Questions Dead-End Cancer Clinical Trials
7. 6 Years Later, 9/11 Health Questions Linger
8. U.S. Physicians Question Presidential Candidates
9. RFID Implant Cancer Questions Concern Patients
10. Study Questions Genetic Screening for Treatable Diseases
11. Mass. Judge Denies Request by Breastfeeding Mother for More Break Time on Medical Licensing Exam
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) will ... during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual ... F. Collen, a pioneer in the field of medical informatics, this prestigious award is ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Fla. , Oct. 2, 2017  AllianceRx Walgreens ... company formed by Walgreens and pharmacy benefit manager Prime ... its new brand, which included the unveiling of new ... , as well as at a few other ... the new brand to patients, some of whom will ...
(Date:9/28/2017)... 28, 2017 Cohen Veterans Bioscience and Early ... of wearable and home sensors for real-time monitoring of ... Foundation, a nonprofit organization focused on disruptive health solutions ... affordable analytical system to record and integrate behavioral, cognitive, ... ...
(Date:9/25/2017)... 2017  EpiVax, Inc., a leader in the ... today announced the launch of EpiVax Oncology Inc., ... therapeutic cancer vaccines. EpiVax has provided $500,000 in ... enabling technologies to the new precision immunotherapy venture. ... Oncology as Chief Executive Officer. Gad brings over ...
Breaking Medicine Technology: